Servier Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SERVIER, and what generic alternatives to SERVIER drugs are available?
SERVIER has two approved drugs.
There are fourteen US patents protecting SERVIER drugs.
There are two hundred and thirty patent family members on SERVIER drugs in forty-three countries and nine supplementary protection certificates in eight countries.
Drugs and US Patents for Servier
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | 9,850,277 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Servier | VORANIGO | vorasidenib | TABLET;ORAL | 218784-002 | Aug 6, 2024 | RX | Yes | Yes | 10,172,864 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | 11,667,673 | ⤷ Sign Up | ⤷ Sign Up | ||||
Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Servier Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 258685 | ⤷ Sign Up |
Hong Kong | 1217948 | ⤷ Sign Up |
Serbia | 57730 | ⤷ Sign Up |
Serbia | 62919 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2013107291 | ⤷ Sign Up |
Mexico | 2020004513 | ⤷ Sign Up |
Hungary | E057264 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Servier Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2804851 | PA2023529 | Lithuania | ⤷ Sign Up | PRODUCT NAME: IVOSIDENIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, TAUTOMERAS, IZOTOPOLOGAS ARBA HIDRATAS; REGISTRATION NO/DATE: EU/1/23/1728 20230504 |
2804851 | 301243 | Netherlands | ⤷ Sign Up | PRODUCT NAME: IVOSIDENIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT, TAUTOMEER, ISOTOPOLOOG OF HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/23/1728 20230508 |
2804851 | 122023000051 | Germany | ⤷ Sign Up | PRODUCT NAME: LVOSIDENIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ, TAUTOMER, ISOTOPOLOG ODER HYDRAT DAVON; REGISTRATION NO/DATE: EU/1/23/1728 20230504 |
2804851 | LUC00315 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: IVOSIDENIB OR A PHARMACEUTICALLY ACCEPTABLE SALT, TAUTOMER, ISOTOPOLOGUE OR HYDRATE THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/23/1728 20230508 |
2804851 | C20230022 00409 | Estonia | ⤷ Sign Up | PRODUCT NAME: IVOSIDENIIB;REG NO/DATE: EU/1/23/1728 08.05.2023 |
2804851 | CR 2023 00025 | Denmark | ⤷ Sign Up | PRODUCT NAME: IVOSIDENIB ELLER ET FARMACEUTISK ACCEPTABELT SALT, TAUTOMER, ISOTOPOLOG ELLER HYDRAT DERAF; REG. NO/DATE: EU/1/23/1728 20230508 |
2804851 | CA 2023 00025 | Denmark | ⤷ Sign Up | PRODUCT NAME: IVOSIDENIB ELLER ET FARMACEUTISK ACCEPTABELT SALT, TAUTOMER, ISOTOPOLOG ELLER HYDRAT DERAF; REG. NO/DATE: EU/1/23/1728 20230508 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.